| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
Natural product from Reynoutria japonica; Emodin metabolite
|
|---|---|
| ln Vitro |
The viability of HUVECs is unaffected by emodin-6-O-β-D-glucoside (0~20 μM; 24 hours)[1]. To reduce high glucose-mediated membrane disruption, Emodin-6-O-β-D-glucoside (0~10 μM; 6 hours; HUVECs) inhibits the upregulation of VCAM-1, ICAM-1, and E-selectin expression. It also reduces the amounts of MCP-1 and IL-8 mRNA that are induced by high glucose.[1]. There is a reduction in the quantity of THP-1 cells adhering to high glucose-induced HUVECs when emodin-6-O-β-D-glucoside (10 μM; 6 hours) is added[1]. When p65 NF-κB expression levels are elevated, high-glucose-induced ROS formation is significantly inhibited by emodin-6-O-β-D-glucoside pretreatment [1].
|
| ln Vivo |
Emodin-6-O-β-D-glucoside (0~9 mg/mouse; i.v.) significantly reduces the dye leakage from the peritoneum that is brought on by elevated glucose levels[1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HUVECs Tested Concentrations: 0~20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Did not affect cell viability. Western Blot Analysis[1] Cell Types: HUVECs Tested Concentrations: 0~10 μM Incubation Duration: 6 hrs (hours) Experimental Results: Inhibited high glucose-induced increase expression of VCAM-1, ICAM-1 and E-selectin. RT-PCR[1] Cell Types: HUVECs Tested Concentrations: 0~10 μM Incubation Duration: 6 hrs (hours) Experimental Results: Resulted in diminished expression levels of high glucose-induced MCP-1 and IL-8 mRNA. Immunofluorescence[1] Cell Types: HUVECs Tested Concentrations: 10 μM Incubation Duration: 6 hrs (hours) Experimental Results: Resulted in a decrease in the number of THP-1 cells adhering to high glucose-induced HUVECs. |
| Animal Protocol |
Animal/Disease Models: Mouse[1]
Doses: 0~9 mg/mouse Route of Administration: I.v. Experimental Results: Markly inhibited peritoneal leakage of dye induced by high glucose. |
| References | |
| Additional Infomation |
Clicoemodin has been reported in Rumex patientia with data available.
Emodin-6-O-β-D-glucoside (EG), a new active compound from Reynoutria japonica, has recently been shown to exert potent anti-inflammatory and barrier protective effects in human umbilical vein endothelial cells (HUVECs) and in mice. Vascular inflammatory process has been suggested to play a key role in initiation and progression of atherosclerosis, a major complication of diabetes mellitus. Thus, we attempted to determine whether EG can suppress the vascular inflammatory process induced by high glucose (HG) in HUVECs and mice. Data showed that HG induced markedly increased vascular permeability, monocyte adhesion, expressions of CAMs, formation of ROS, and activation of NF-κB. Remarkably, all of the above-mentioned vascular inflammatory effects of HG were attenuated by pretreatment with EG. Vascular inflammatory responses induced by HG are critical events underlying development of various diabetic complications; therefore, our results suggest that EG may have significant therapeutic benefits against diabetic complications and atherosclerosis. [1] |
| Molecular Formula |
C21H20O10
|
|---|---|
| Molecular Weight |
432.3775
|
| Exact Mass |
432.105
|
| CAS # |
34298-85-6
|
| PubChem CID |
636641
|
| Appearance |
Light yellow to yellow solid
|
| LogP |
0.9
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
700
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O[C@@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
UBVJENDWBOVRBS-FHTSYUTFSA-N
|
| InChi Code |
InChI=1S/C21H20O10/c1-7-2-9-14(11(23)3-7)18(27)15-10(16(9)25)4-8(5-12(15)24)30-21-20(29)19(28)17(26)13(6-22)31-21/h2-5,13,17,19-24,26,28-29H,6H2,1H3/t13-,17+,19+,20-,21+/m1/s1
|
| Chemical Name |
1,8-dihydroxy-3-methyl-6-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyanthracene-9,10-dione
|
| Synonyms |
Glucoemodin; 34298-85-6; 1,8-dihydroxy-3-methyl-6-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyanthracene-9,10-dione; Emodin 6-O-beta-D-glucoside; AC1LCSMQ; Emodin 6-O-beta-glucoside; DTXSID60348379; Emodin 6-O-β-D-glucoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3128 mL | 11.5639 mL | 23.1278 mL | |
| 5 mM | 0.4626 mL | 2.3128 mL | 4.6256 mL | |
| 10 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
